Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Goy Underscores Impact of BTK Inhibitors in Relapsed/Refractory MCL

April 7th 2020

Andre Goy, MD, MS, discusses the utility of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Dr. Wang on Ongoing Research in MCL

April 7th 2020

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

KTE-X19 Pivotal MCL Data Published in NEJM as FDA Weighs Approval

April 4th 2020

Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma were published in the New England Journal of Medicine, as the FDA considers a biologics license application for the CAR T-cell therapy for an approval in this setting.

Dr. Miklos on the Safety Profile of KTE-X19 in MCL

April 2nd 2020

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Infusion-Schedule Challenges Halt Exploration of Carfilzomib/Ibrutinib in R/R MCL

March 25th 2020

Hun Ju Lee, MD, discusses the implications of phase I results regarding the combination of carfilzomib and ibrutinib in relapsed/refractory mantle cell lymphoma.

High-Dose Cytarabine Induction Regimens Elicit High Responses in Transplant-Eligible MCL

March 23rd 2020

Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.

Cirmtuzumab/Ibrutinib Combo Active in Mantle Cell Lymphoma

March 12th 2020

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCL

March 10th 2020

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.

Dr. Ritchie on Immunological Recovery With Venetoclax and Ibrutinib in MCL

March 5th 2020

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Dr. Wang on the Safety Profile of KTE-X19 in MCL

March 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

KTE-X19 Poised to Have Promising Future in MCL Paradigm

February 23rd 2020

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Bendamustine Plus Rituximab Shows Promise as Induction Therapy in Mantle Cell Lymphoma

February 20th 2020

Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.

Dr. Ritchie on the Rationale of the AIM Trial in Relapsed/Refractory MCL

February 18th 2020

David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).

Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL

February 14th 2020

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

New BTK Inhibitor Expands Treatment Options for Patients With MCL

February 11th 2020

Javier Munoz, MD, MS, FACP, discusses zanubrutinib’s path to approval in mantle cell lymphoma and its future potential.

Dr. Ramakrishnan on Use of CAR T-Cell Therapy in MCL

February 11th 2020

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL

February 11th 2020

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

FDA Grants Priority Review to KTE-X19 in Mantle Cell Lymphoma

February 10th 2020

The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Dr. Ritchie on the Immunologic Impact of Long-Term Venetoclax/Ibrutinib in R/R MCL

February 8th 2020

David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Rule Reflects on Continued Benefit With Ibrutinib in Relapsed/Refractory MCL

February 7th 2020

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.